Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ETRM - IMO, their delay of their ADCOM really hurt them along with their ATM that they've been using. i think the ATM has been pushing it down a lot. First their ADCOM took longer then expected to get, then they get it and then it's delayed, and combine that with the BIO selloff and then even still, the June Adcom date was just too far off.
It's still too far off right now though and there's also info of them wanting to increase their allowed shares. i don't have the link in front of me, but it's a lot. I think 75M more is what they want.
I'm just hoping for a quick pop back to the $1.90 area to get even. There's the 200 DMA at $1.61 which I should have waited for and will probably be tested. But can't always be in front of computer and don't like placing blind bids.
With any type of IBB rebound (even temporary), it should move fast back up to $1.90-$2.00. Just my $.02
ETRM - Added 3,300 @ $1.69 - Average now at $1.89
Just looking for a pop back to even (now $1.89) or near and I'm out then. Figure I have to claw and scratch back one by one.
Status Filled at $1.6899
Symbol ETRM
Description ENTEROMEDICS INC COM NEW
Action Buy
Quantity 3,300 Shares
Order Date 04/07/2014, 01:42:39 PM ET
Cancel Date
Order Number D07PLGL
Yup, more downside for most of us here with the bios.
I am still believing in the individual ones that I have as their stories haven't changed much. Their covers are banged up and the corners torn, a few pages have been ripped out here and there, but the story inside remains mostly the same. So am just waiting for them to be told.
Today is done, good, bad, or otherwise. Have a good weekend and let's see what tomorrow (next week) brings.
IDRA is presenting at the AACR (amer assoc cancer research) on Monday afternoon (after the close I believe as its 1-5pm San Diego time). My hopes are that they are releasing additional data points or any other info to backup their recent positive study.
I'm not planning to average down at the moment and am still believing in it's ability to bounce back. I don't have too much available to avg down as I'll be needing to remove some money from the account.
IDRA Presentation at AACR : April 7th 1PM-5PM (San Diego - PST)
TITLE:
IMO-8400, a selective antagonist of TLRs 7, 8 and 9, inhibits MYD88 L265P mutation-driven signaling and cell survival: A potential novel approach for treatment of B-cell lymphomas harboring MYD88 L265P mutation
In studies of B-cell lymphoma, Staudt and colleagues have identified oncogenic mutations in the signaling pathways associated with the B-cell receptor (BCR) and, more recently, the MYD88 L265P mutation (Ngo et al, Nature 2011, 470:115). MYD88 is a key adaptor protein in the Toll-like Receptor (TLR) signaling pathway. It has been shown that the MYD88 L265P mutation leads to the over activation of the TLRs 7 and 9 signaling pathway, whereas blocking of this pathway decreased cell survival, providing a rationale for targeting TLRs 7 and 9 signaling as a therapeutic approach (Lim et al, AACR 2013, #2332). The MYD88 L265P mutation is reported to be present in over 90% of Waldenström’s macroglobulinemia (WM) patients, 29% of patients with activated B-cell-like (ABC) diffuse large B cell lymphoma (DLBCL), and in other B-cell lymphomas. We evaluated IMO-8400, an antagonist for TLRs 7, 8 and 9, in preclinical studies employing three cell lines with the MYD88 L265P mutation (OCI-Ly3, OCI-Ly10 and TMD8), primary bone marrow cells from a WM patient with the mutation, and a control GCB-DLBCL cell line SU-DHL-6 with wild-type MYD88. The presence of MYD88 L265P mutation was confirmed by allele-specific PCR and Sanger sequencing. All cell lines expressed TLRs 7 and 9. Treatment of mutation-positive cell lines with IMO-8400 resulted in dose- and duration-dependent decreases in multiple parameters of cell activation, including cell survival (EC50: 0.95 µM and ~5 µM, with and without use of lipid, respectively), phosphorylation of BTK, IRAK1, IRAK4, NF-?B, STAT3 and p38 (assayed by Western blot), and secretion of cytokines including IL-10, MIG and IL-2R. Gene array analysis indicated that IMO-8400 inhibited the expression of several genes in the NF-?B and JAK/STAT pathways, including NFKB1, TNFSF10, STAT3 and IL2RA. IMO-8400 also inhibited cell survival and cytokine secretion in cells from the WM patient. In a murine model of disseminated OCI-LY10, IMO-8400 as a single treatment agent showed potent anti-tumor activity in vivo, with dose-dependent increase in animal survival. Treatment was well-tolerated at all dose levels. In a subcutaneous tumor model, growth of even well-established tumor nodules (approximately 500 mm³) was significantly inhibited by IMO-8400 treatment, and this effect correlated with decreased I?Ba phosphorylation and IL-10 expression (gene and protein) in tumor cells as well as decreased human IL-10 in the serum of the mice. In contrast, IMO-8400 treatment had no effects on control SU-DHL-6 cells in vitro or in vivo. Our studies show that IMO-8400 inhibits oncogenic MYD88 L265P-mediated cell survival and provides a novel approach for treatment of patients with this mutation. A Phase 1/2 trial of IMO-8400 in patients with WM is now open for enrollment.
link: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3404&sKey=de3e8036-5855-4dba-93cf-0df382ff49e5&cKey=c3dbcd4b-7d20-4332-b345-5c44a08d67e3&mKey=6ffe1446-a164-476a-92e7-c26446874d93
RGDX - I made $21 profit on the last bunch so we're still lunch friends ($900 overall on it) to visit and have a beer.
No emotions in it for me. It did a double bottom (dec-24 and March-24) around $1.10-$1.20. Seems support there.
Had HUGE volume around 10M dwarfing anything before and surprised with new sales agreements yesterday. It popped to $1.55ish and then sold off on the news and now IBB/Bios pulling it down more?
So, a return to $1.10-$1.20 puts it right back where it was, before the good news yesterday. All adds up to..."on watch for me again." Would only be looking for a $.10-.20 move. Worth a looksee.
one of the guys I follow on twitter is @jamison_gaddy , he is always posting natty gas tweets and charts with support and resistance levels and the such. he likes to play them a lot.
just an fyi for you if interested and if its the same sector.
Welcome to the Board Azy, looking forward to reading your posts and plays :)
it shouldn't hurt :) I haven't followed PGNX like most have. Just too many to keep track of, so some I just pass on. I have faith in ETRM and SYN to rebound to at least former higher trading levels.
IDRA Presentation at AACR : April 7th 1PM-5PM (San Diego - PST)
TITLE:
IMO-8400, a selective antagonist of TLRs 7, 8 and 9, inhibits MYD88 L265P mutation-driven signaling and cell survival: A potential novel approach for treatment of B-cell lymphomas harboring MYD88 L265P mutation
In studies of B-cell lymphoma, Staudt and colleagues have identified oncogenic mutations in the signaling pathways associated with the B-cell receptor (BCR) and, more recently, the MYD88 L265P mutation (Ngo et al, Nature 2011, 470:115). MYD88 is a key adaptor protein in the Toll-like Receptor (TLR) signaling pathway. It has been shown that the MYD88 L265P mutation leads to the over activation of the TLRs 7 and 9 signaling pathway, whereas blocking of this pathway decreased cell survival, providing a rationale for targeting TLRs 7 and 9 signaling as a therapeutic approach (Lim et al, AACR 2013, #2332). The MYD88 L265P mutation is reported to be present in over 90% of Waldenström’s macroglobulinemia (WM) patients, 29% of patients with activated B-cell-like (ABC) diffuse large B cell lymphoma (DLBCL), and in other B-cell lymphomas. We evaluated IMO-8400, an antagonist for TLRs 7, 8 and 9, in preclinical studies employing three cell lines with the MYD88 L265P mutation (OCI-Ly3, OCI-Ly10 and TMD8), primary bone marrow cells from a WM patient with the mutation, and a control GCB-DLBCL cell line SU-DHL-6 with wild-type MYD88. The presence of MYD88 L265P mutation was confirmed by allele-specific PCR and Sanger sequencing. All cell lines expressed TLRs 7 and 9. Treatment of mutation-positive cell lines with IMO-8400 resulted in dose- and duration-dependent decreases in multiple parameters of cell activation, including cell survival (EC50: 0.95 µM and ~5 µM, with and without use of lipid, respectively), phosphorylation of BTK, IRAK1, IRAK4, NF-?B, STAT3 and p38 (assayed by Western blot), and secretion of cytokines including IL-10, MIG and IL-2R. Gene array analysis indicated that IMO-8400 inhibited the expression of several genes in the NF-?B and JAK/STAT pathways, including NFKB1, TNFSF10, STAT3 and IL2RA. IMO-8400 also inhibited cell survival and cytokine secretion in cells from the WM patient. In a murine model of disseminated OCI-LY10, IMO-8400 as a single treatment agent showed potent anti-tumor activity in vivo, with dose-dependent increase in animal survival. Treatment was well-tolerated at all dose levels. In a subcutaneous tumor model, growth of even well-established tumor nodules (approximately 500 mm³) was significantly inhibited by IMO-8400 treatment, and this effect correlated with decreased I?Ba phosphorylation and IL-10 expression (gene and protein) in tumor cells as well as decreased human IL-10 in the serum of the mice. In contrast, IMO-8400 treatment had no effects on control SU-DHL-6 cells in vitro or in vivo. Our studies show that IMO-8400 inhibits oncogenic MYD88 L265P-mediated cell survival and provides a novel approach for treatment of patients with this mutation. A Phase 1/2 trial of IMO-8400 in patients with WM is now open for enrollment.
link: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3404&sKey=de3e8036-5855-4dba-93cf-0df382ff49e5&cKey=c3dbcd4b-7d20-4332-b345-5c44a08d67e3&mKey=6ffe1446-a164-476a-92e7-c26446874d93
Thanks Smurf, appreciated. I like these types of articles.
I still have:
- hesse's histogram/other posts to study
- Norm's watchlist QXRPY, etc.
- fam401's CTXI
- Smurf's IGXT and a few others on his list
- anything else i left out
Am behind on a lot of things and also need to run some of my scans (which identified SARA, IDN, and a few others for me right before they took off) to get some non-bios to look into.
I believe $heff has stated recently that he's not going to post his buys and sells real time on his board anymore. I'm sure he gets flack when he does and when he doesn't. In any case...ETRM (am holding) and SYN (also holding) may get some additional eyes on them as he email alerted that he bought SYN, PGNX, and ETRM today.
Another guy I follow Michele Ciani (biotech trader) mentioned looking for an entry in SYN also. So, as mentioned earlier, I believe a lot of eyes will be focused upon (and hopefully $$$ too) towards SYN very soon. I believe April 25th is their presentation (data date) so that's getting a bit closer :)
ARIA has been on my unofficial watch list for some time. I've been close to pulling the trigger a few times only to have those fun rumors (buyouts) beating me out by a day or so, and I don't want to chase it.
I haggle with them the best i can but we've had 3 surgeries in the family in the past year totaling $150,000+. Even with good insurance paying most of that, my on-going problems keep adding to it. At least my wife's and son's surgeries solved their problems (knock on wood).
Great history there. I will have to take $$$ out to pay medical bills, so only watching for now.
Thx, bed...someone needs sleep. Subliminal post there Hesse.
IGXT - Past History - I fully believe in the theory or playing stocks that you've hit a few times and done well, and/or know why you failed. You've followed them for a while so should have a good feel for it. Go get 'em!
March Results +6,668.04
March has been my best month to date and beat my goal of $6,052. But March is done now and April is here and who gives a crap about the past.
Both in February & March I started the months down about $3,000-$4,500, so hoping that I can turn around my current holdings of -$7,000 into gains as well.
As stated previously, all my holdings have reasons to believe ..link here: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=99599510&txt2find=reason
Holding ELTP, ETRM, IDRA, SYN
My goal for April is $4,052, which would be a 11k turnaround by the end of the month. My hope is to get to even in my holdings and / or eek out some small profits and then enter better trades, or same stocks at better levels.
I need to reinforce my stop losses and get out of any trades when my life is hectic and distractions enter. Live to Trade Another Day is the thing I need to work on. My entrances seem to almost always do well and lead to a profit, I just need to work on taking that profit and exiting. And / or when the market changes, change with it. Live and Learn.
Best of Luck to all.
Fantastico! Money in the bank. Congrats as I know it was a nice long play for you. Stay focused.
I personally am staying away from APPY and a lot of these offerings at the moment. Am going to play data, ADCOM and PDUFA plays instead. Just my feeling, but not as much love for small bios at the moment.
Well, in a few years, we all hope to be rich enough to have assistants to yell our orders at. Smithers! Sell RGDX now you moron! That'll work too.
fantastic horent! way to play it. As you know I've traded it a few times, done well, and have had it on my radar to enter again, only no available cash to do so. Stay focused and don't chase, just like you did this time.
nice job! even in this type of bio market is a good trade in my eyes.
In the same boat with you on SYN Norm. I think not getting the Pertusis data when most people thought it was coming, hurt the shares some too, but with the April catalyst and as Smurf mentions, its a highly watched/traded bio on a LOT of peep's lists, I'm mostly confident of getting back to $3.13 (my buy in) and past also. Best of Luck to us.
RGDX - Pulled into a parking lot and put a market order in for the remaining 700 shares of RGDX @ $1.47. It hit $1.56 today. You just never know.
Loss of $39.87 on these 3700 remaining shares. Made $70.09 on previous sell, so $21 profit - woot :)
RGDX - Sold 3,000 Premarket at $1.39 and $1.43. Have partial order fill of 700 remaining. Am looking to get out at break evenish and am not sure of availability this AM.
RGDX News: Announces Contracts With Six New Provider Networks
link: http://boardvote.com/symbol/RGDX/communique/601688
LOS ANGELES, April 3, 2014 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has signed agreements with six additional health plans across 10 states bringing the Company's total national contracted membership to more than 174 million lives.
The new agreements include additional Blue Cross Blue Shield contracts in Arizona, Iowa, South Dakota, Pennsylvania, Delaware, and West Virginia. The Company also signed new agreements with an Independent Physician Association (covering two states) in the North West region and a Commercial Health Plan (covering two states) in the North East region of the United States.
These partnerships mark a further step forward in Response Genetics' growing managed care contracting program. With these agreements, Response Genetics is now in-network with a total of thirteen Blue Cross Blue Shield health plans, which brings the total number of "Blues" subscribers with direct access to Response Genetics to approximately 23 million. Among Response Genetics' other Blue Cross Blue Shield contracts are Blue Cross and Blue Shield of Illinois, Blue Shield of California and CareFirst BlueCross BlueShield (Maryland, Washington, DC and Northern Virginia).
In addition to its recently launched proprietary ResponseDX: Tissue of Origin™ diagnostic test, Response Genetics' molecular testing primarily focuses on therapy-selection for patients with lung, colon, gastric, melanoma, and thyroid cancers. Response Genetics' menu of genomic assays provides treating physicians actionable information on a patient's tumor by predicting which course of therapy will work best for that patient. In this way, Response Genetics' participation with these Blues plans should improve plan members' access to individually-tailored medicine.
About Response Genetics, Inc.
Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit www.responsegenetics.com.
CYTR News : CytRx to present updated aldoxorubicin study results at AACR meeting
link: http://www.theflyonthewall.com/permalinks/entry.php/CYTRid1988125/CYTR-CytRx-to-present-updated-aldoxorubicin-study-results-at-AACR-meeting
CytRx announced that positive preclinical results from an in vivo study of aldoxorubicin in an animal model of glioblastoma will be presented at the American Association for Cancer Research Annual Meeting being held April 5-9, 2014 in San Diego, CA. CytRx announced data from the trial, which demonstrated that aldoxorubicin significantly increased survival almost 2½ fold compared to doxorubicin treatment in an in vivo xenograft tumor model employing growth of human glioblastoma multiforme tumors in mouse brains. Aldoxorubicin, but not doxorubicin, also demonstrated preferential accumulation and prolonged retention in the tumor tissue. These data, combined with aldoxorubicin’s favorable safety profile, support the current evaluation of aldoxorubicin as a treatment for patients with GBM tumors.
Best of Luck
It could very well be your company's plan then. Each is different in what they will and won't allow.
Making money is good. Locking in profit is better :)
I have Fidelity 401k Brokerage Link and was able to buy ELTP as well. I believe in order to purchase over 10,000 shares of penny stocks, I had to call first and listen and agree to the disclaimers.
Best of Luck
ACST - thanks. will have to sit this one out until it settles after the Seeking Alpha article and cash is available, otherwise its still high on my list for another play.
When dealing with health and children, always better to be overly cautious as they can't always communicate the problem. good move.
Insert biotech symbol in space below...
"Still watching ____ fall continuously waiting for the right time to jump in."
applies to many.
Today : Anyone catch anything? Any bouncebacks or runners?
New quarter starts tomorrow.
OT: Hope Smurf is playing hooky and attending a baseball game today. I always try and plan on doing so with my kids (if schedule and weather allows) - it's a dad's right!
As a Cub's fan, we typically have one day to be totally positive and that's Opening Day, because its pretty much downhill from there :)
ELTP - Is a bit of a wall today with large buyer sitting on $.41. It's been working through those shares for a while...slowly.
Holding ELTP, ETRM, IDRA, RGDX, SYN
Only RGDX positive today 4%. Maybe bigger companies get the faith today and it takes time for smaller caps to feel the love upon the IBB bounce.
Happy Opening Day Baseball Fans!
Let's Hope so Norm. What's on your watchlist?